DK3173102T3 - FGFR-FC-fusionsprotein og anvendelse deraf - Google Patents
FGFR-FC-fusionsprotein og anvendelse deraf Download PDFInfo
- Publication number
- DK3173102T3 DK3173102T3 DK16205128.8T DK16205128T DK3173102T3 DK 3173102 T3 DK3173102 T3 DK 3173102T3 DK 16205128 T DK16205128 T DK 16205128T DK 3173102 T3 DK3173102 T3 DK 3173102T3
- Authority
- DK
- Denmark
- Prior art keywords
- fgfr
- fusion protein
- fusion
- protein
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Wood Science & Technology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110132218A CN102219860B (zh) | 2011-05-20 | 2011-05-20 | FGFR-Fc融合蛋白及其用途 |
| EP12788998.8A EP2711376B1 (en) | 2011-05-20 | 2012-05-18 | Fgfr-fc fusion protein and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3173102T3 true DK3173102T3 (da) | 2020-02-24 |
Family
ID=44776585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16205128.8T DK3173102T3 (da) | 2011-05-20 | 2012-05-18 | FGFR-FC-fusionsprotein og anvendelse deraf |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9273137B2 (da) |
| EP (2) | EP3173102B1 (da) |
| JP (1) | JP2014513941A (da) |
| KR (2) | KR20130119978A (da) |
| CN (1) | CN102219860B (da) |
| AU (1) | AU2012261412B2 (da) |
| BR (1) | BR112013022285B1 (da) |
| CA (1) | CA2834584C (da) |
| DK (1) | DK3173102T3 (da) |
| RU (1) | RU2560573C2 (da) |
| WO (1) | WO2012159550A1 (da) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102219860B (zh) * | 2011-05-20 | 2012-09-12 | 烟台荣昌生物工程有限公司 | FGFR-Fc融合蛋白及其用途 |
| KR102132149B1 (ko) * | 2012-07-24 | 2020-07-09 | 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 | 융합 단백질 및 그의 방법 |
| CA2898415A1 (en) | 2013-01-16 | 2014-07-24 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders |
| US9957313B2 (en) | 2013-03-15 | 2018-05-01 | Remegen, Ltd. | FGFR-FC fusion proteins and the use thereof |
| MX2015015426A (es) * | 2013-05-23 | 2016-06-10 | Five Prime Therapeutics Inc | Metodos de tratamiento de cancer. |
| CN105983093A (zh) * | 2015-02-11 | 2016-10-05 | 烟台荣昌生物工程有限公司 | 血管新生因子融合蛋白在制备用于治疗与血管新生相关的眼部疾病药物中的应用 |
| SG11201900074WA (en) | 2016-07-07 | 2019-02-27 | Therachon Sas | Soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides and uses thereof |
| EP3595704A1 (en) * | 2017-03-17 | 2020-01-22 | Vaximm AG | Novel pd-l1 targeting dna vaccine for cancer immunotherapy |
| RU2760738C1 (ru) | 2018-12-07 | 2021-11-30 | Ремеджен Ко., Лтд. | Бифункциональный ингибитор ангиогенеза и его применение |
| CN116143941B (zh) * | 2022-09-08 | 2024-06-04 | 浙江省血液中心 | 一种KIR3DL1-IgG-Fc融合重组蛋白、应用及试剂盒 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL99120A0 (en) | 1991-08-07 | 1992-07-15 | Yeda Res & Dev | Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them |
| AU3224700A (en) * | 1999-02-08 | 2000-08-25 | Chiron Corporation | Fibroblast growth factor receptor-immunoglobulin fusion |
| DE102005007665A1 (de) * | 2005-02-19 | 2006-08-31 | Degussa Ag | Folie auf Basis eines Polyamidblends |
| EP2083081A1 (en) * | 2005-07-22 | 2009-07-29 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with FGFR fusion proteins |
| EP2044115A2 (en) * | 2006-06-12 | 2009-04-08 | Receptor Biologix, Inc. | Pan-cell surface receptor- specific therapeutics |
| RU2341198C2 (ru) * | 2006-11-27 | 2008-12-20 | ФГУ Ростовский научно-исследовательский онкологический институт Росздрава | Способ оценки ангиогенных факторов при химиотерапии рака молочной железы |
| CL2007003411A1 (es) * | 2006-11-28 | 2008-07-04 | Centelion | Proteina fusion que consiste en una region fc de una inmunoglobulina con un fragmento o dominio soluble de un receptor para fgf; polinucleotido que la codifica y vector y celula que lo comprenden; composicion farmaceutica que comprende la proteina fu |
| ZA200903134B (en) * | 2006-11-28 | 2010-08-25 | Centelion | Modified soluble FGF receptor FC fusions with improved biological activity |
| WO2008133873A2 (en) * | 2007-04-25 | 2008-11-06 | Aveo Pharmaceuticals, Inc. | Fgf-binding fusion proteins |
| FR2933702A1 (fr) * | 2008-07-08 | 2010-01-15 | Sanofi Aventis | Antagonistes specifiques du recepteur fgf-r4 |
| US8338569B2 (en) * | 2008-08-04 | 2012-12-25 | Five Prime Therapeutics, Inc. | FGFR extracellular domain acidic region muteins |
| US8614183B2 (en) * | 2009-11-13 | 2013-12-24 | Five Prime Therapeutics, Inc. | Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2 |
| CN102219860B (zh) * | 2011-05-20 | 2012-09-12 | 烟台荣昌生物工程有限公司 | FGFR-Fc融合蛋白及其用途 |
| CN102219859B (zh) * | 2011-05-20 | 2012-09-12 | 烟台荣昌生物工程有限公司 | 拮抗血管新生诱导因子的融合蛋白及其用途 |
-
2011
- 2011-05-20 CN CN201110132218A patent/CN102219860B/zh active Active
-
2012
- 2012-05-18 EP EP16205128.8A patent/EP3173102B1/en active Active
- 2012-05-18 DK DK16205128.8T patent/DK3173102T3/da active
- 2012-05-18 WO PCT/CN2012/075706 patent/WO2012159550A1/zh active Application Filing
- 2012-05-18 CA CA2834584A patent/CA2834584C/en active Active
- 2012-05-18 AU AU2012261412A patent/AU2012261412B2/en active Active
- 2012-05-18 KR KR1020137023245A patent/KR20130119978A/ko active Application Filing
- 2012-05-18 EP EP12788998.8A patent/EP2711376B1/en active Active
- 2012-05-18 RU RU2013140184/10A patent/RU2560573C2/ru active
- 2012-05-18 BR BR112013022285-9A patent/BR112013022285B1/pt active IP Right Grant
- 2012-05-18 JP JP2014505502A patent/JP2014513941A/ja active Pending
- 2012-05-18 KR KR1020167001261A patent/KR101660336B1/ko active IP Right Grant
-
2013
- 2013-03-15 US US13/842,345 patent/US9273137B2/en active Active
-
2016
- 2016-02-29 US US15/056,207 patent/US20160176945A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014513941A (ja) | 2014-06-19 |
| AU2012261412A1 (en) | 2013-08-29 |
| RU2560573C2 (ru) | 2015-08-20 |
| AU2012261412B2 (en) | 2016-02-25 |
| CA2834584A1 (en) | 2012-11-29 |
| EP3173102B1 (en) | 2019-11-20 |
| EP2711376A1 (en) | 2014-03-26 |
| US20160176945A1 (en) | 2016-06-23 |
| KR101660336B1 (ko) | 2016-09-27 |
| US20130195864A1 (en) | 2013-08-01 |
| WO2012159550A1 (zh) | 2012-11-29 |
| RU2013140184A (ru) | 2015-07-10 |
| EP2711376B1 (en) | 2018-07-25 |
| BR112013022285A2 (pt) | 2016-12-06 |
| CN102219860A (zh) | 2011-10-19 |
| CN102219860B (zh) | 2012-09-12 |
| CA2834584C (en) | 2019-05-14 |
| BR112013022285B1 (pt) | 2020-05-12 |
| US9273137B2 (en) | 2016-03-01 |
| EP3173102A1 (en) | 2017-05-31 |
| KR20160011241A (ko) | 2016-01-29 |
| KR20130119978A (ko) | 2013-11-01 |
| EP2711376A4 (en) | 2015-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3321287T3 (da) | Fusionsproteiner og kombinationsvacciner | |
| DK2914291T3 (da) | Anti-komplement-c1s-antistoffer og anvendelser deraf | |
| CO7020851A2 (es) | Proteínas y péptidos modificados | |
| DK2794654T3 (da) | Anti-phf-tau-antistoffer og deres anvendelser | |
| DK2920313T3 (da) | Rekombinante adenovira og anvendelse deraf | |
| DK3597644T3 (da) | Kationiske aminlipider og anvendelser deraf | |
| BR112014012137A2 (pt) | anticorpos anti-fgfr2 e suas utilizações | |
| DK2920197T3 (da) | Prolinlåste sammenhæftede peptider og anvendelser deraf | |
| DK3381943T3 (da) | Anti-kit-antistoffer og anvendelser deraf | |
| DK3333188T3 (da) | Anti-NGF-antistoffer og deres anvendelse | |
| DK3415157T3 (da) | N-acyldipeptidderivater og anvendelser deraf | |
| DK2812443T3 (da) | Cd47-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK2785375T3 (da) | Anti-pd-l1-antistoffer og anvendelser deraf | |
| DK3556774T3 (da) | Anti-CD40-antistoffer og anvendelser deraf | |
| BR112015003838A2 (pt) | formulações de anticorpo e proteína | |
| BR112014009050A2 (pt) | pirrolbenzodiazepinas e conjugados destas | |
| DK3346008T3 (da) | Rekombinante mikroorganismer og anvendelser deraf | |
| EP2877854A4 (en) | FUSION PROTEINS AND METHOD THEREFOR | |
| DK2552434T3 (da) | Peptider og anvendelse deraf | |
| DK2726092T3 (da) | Serpin-fusionspolypeptider og fremgangsmåder til anvendelse deraf | |
| DK3173102T3 (da) | FGFR-FC-fusionsprotein og anvendelse deraf | |
| DK3197164T3 (da) | Afkodningsanordning og afkodningsfremgangsmåde | |
| DK2668210T3 (da) | Anti-kit antistoffer og anvendelser deraf | |
| DK3434775T3 (da) | Protein med nukleaseaktivitet, fusionsproteiner og anvendelser deraf | |
| DK3453723T3 (da) | Anti-ASIC1-antistoffer og anvendelser deraf |